COMy 2017 | Daratumumab: no evidence of disease after treatment?
Torben Plesner
• 21 Apr 2017
Torben Plesner, MD, from the Vejle Hospital and University of Southern Denmark, Vejle, Denmark, discusses promising results from daratumumab trials at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. From the early trials of daratumumab, there is a small subgroup of patients that have no evidence of disease after treatment. There is now an investigation using next generation sequencing to look for signs of any residual disease, and to determine what makes this treatment so effective in these patients.
